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Introduction 
Nitrofurantoin is a frequently used anti-
biotic for treatment and prophylaxis against 
urinary tract infections.  It is a relatively safe 
medication with rare side effects, however, 
cases of severe pulmonary injury secondary 
to its use have been reported.1 We report a 
patient with pulmonary infiltrates with 
eosinophilia, pleural effusion, and interstitial 
lung disease induced by the chronic use of 
nitrofurantoin.  The association of severe 
eosinophilic bronchopneumopathy with 
interstitial fibrosis makes this case rare and 
shows the possible deleterious effect of 
chronic nitrofurantoin use. 
 
Case Report 
An 83-year-old male with a two-year 
history of chronic cough and shortness of 
breath presented with progressive worsening 
of symptoms over the two months prior to 
presentation.  He denied hemoptysis, fever, 
chills, or sick contacts. He was a non-
smoker and denied any occupational 
exposures. 
The patient was taking nitrofurantoin 
100 mg daily for recurrent urinary tract 
infections. It was started two years ago 
before his symptoms began. His past 
medical history was significant for coronary 
artery disease and diabetes mellitus II 
treated with insulin. 
 
 
On physical examination, he had no 
fever.  Oxygen saturation by pulse oximetry 
was 61% on room air and increased to 90% 
on four liters of oxygen.  Bilateral coarse 
crackles were noted on both lung fields, 
more prominent on the right side with 
decreased air entry at the bases.  Laboratory 
workup revealed a normal blood count, 
chemistry, and liver panel.  Arterial blood 
gas analysis revealed hypoxemia with a 
PaO2 of 66 mmHg on 6 liters oxygen, PCO2 
was normal. 
A chest radiograph showed diffuse, 
bilateral infiltrates most concentrated in the 
right upper lobe, and a small right pleural 
effusion. A review of previous chest x-rays 
over the prior two years revealed the same 
findings with temporal progression (see 
Figure 1).  High resolution CT scan of the 
chest showed diffuse fibrosis, right upper 
lobe and lingular consolidation, and small 
right pleural effusion (see Figure 2). 
The patient underwent a bronchoscopy 
with bronchoalveolar lavage and trans-
bronchial biopsies. The bronchoalveolar 
lavage was obtained from the right upper 
lobe and revealed numerous white blood 
cells with significant eosinophilia (25%). 
Fungal and bacterial cultures were negative 
as well as viral PCR, pneumocystis carinii 
pneumonia (PCP) stain,  and acid fast bacilli  
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Figure 1.  A chest x-ray revealed bilateral interstitial infiltrates more prominent in the right 
upper and lower lung and at the periphery.  Also, a small right pleural effusion is noted. 
 
*
*
*
 
Figure 2.  A high resolution CT scan of the lung showed mild right pleural effusion 
(arrow) and right upper lobe, right lower lobe, and lingular infiltrate (stars). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  A transbronchial biopsy showing: (a) a normal alveoli (star) compared to 
thickened alveoli with fibrosis (arrows) and (b) of normal bronchial epithelium (star) with 
numerous eosinophils (arrows) involving the adjacent connective tissue. 
*
*
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(AFB) stain. Transbronchial biopsies from 
the right upper lobe showed fibrosis and 
eosinophilic infiltrates without evidence of 
malignancy (see Figure 3). 
Drug-induced lung toxicity was 
suspected and nitrofurantoin was stopped.  
The patient was treated with prednisone 20 
mg daily.  There was marked clinical and 
radiologic improvement in a follow-up 
examination one month later.   
 
Discussion 
Based on World Health Organization 
criteria2, nitrofurantoin was the “probable” 
cause of the lung toxicity.  There was a 
reasonable time sequence of the lung 
toxicity to administration of the drug.  It was 
unlikely to be attributed to concurrent 
disease or other drugs or chemicals, and 
followed a clinically reasonable response on 
withdrawal of nitrofurantoin. 
Nitrofurantoin has been associated with 
several lung diseases. The first pulmonary 
reaction to nitrofurantoin was described in 
1957.2  Subsequently, cases of bronchiolitis 
obliterans     with     organizing    pneumonia  
(BOOP),3 pulmonary infiltrates with 
eosinophilia (PIE) syndrome,4 diffuse 
alveolar hemorrhage,5 diffuse alveolar 
damage (DAD),6 and acute, subacute, and 
chronic interstitial lung disease have been 
reported.7   
Two forms of nitrofurantoin-induced 
lung injury have been described: acute and 
chronic. The acute form is a hypersensitivity 
reaction (type I or III),8 clinically 
characterized by fever (82%), dyspnea 
(60%), cough (43%), rash (20%), chest pain, 
and cyanosis.9,10 On the other hand, the 
chronic form may be either an allergic or a 
toxic response,8 and usually presents with 
nonspecific symptoms including dyspnea 
(73%), dry cough (63%), and fatigue (37%). 
Fever might also occur in chronic forms but 
it is unusual.10 Oxidative stress also has been 
implicated in lung injury as reported by in 
vivo studies conducted on rats.11  Symptoms 
usually start within a few days in acute 
forms, while chronic forms manifest after 1 
to 6 months of treatment.10 
Among the pulmonary toxicity of 
nitrofurantoin, PIE syndrome rarely has 
been reported.12  It was first described after 
the use of sulfonamide, however, currently 
more than 100 drugs can cause this disease. 
The most common medications causing PIE 
syndromes include antibiotics (e.g., 
minocycline, sulfasalazine, sulfamethoxy-
pyridazine, sulfamethoxazole), angiotensin-
converting enzyme inhibitors, nonsteroidal 
anti-inflammatory drugs, imipramine, and 
carbamazepine. 
The diagnosis of PIE syndrome is 
established by the presence of pulmonary 
infiltrates and eosinophilia, detected in 
blood, bone marrow, bronchoalveolar 
lavage, or lung tissue.13 Marked peripheral 
eosinophilia may not be present primarily 
because of the sequestration of eosinophils 
in the lung tissue or secondary to previous 
use of steroids.  
The cause of PIE syndrome is not only 
limited to drugs.  It includes infectious 
causes (e.g., fungi or parasites), and 
idiopathic and autoimmune diseases.14 It 
also was reported in patients with AIDS, 
lymphoma, a variety of inflammatory lung 
diseases, and collagen vascular diseases.15 
Treatment of PIE syndrome varies 
depending on the etiology.16  In case of 
drug-induced syndrome, the treatment 
consists of withdrawal of the offending 
agents. The same applies for the other drug-
induced infiltrative lung diseases. Patients 
with mild-to-moderate inflammatory 
interstitial lung diseases (ILD) will respond 
quickly, whereas drugs that cause acute 
interstitial reactions or pulmonary fibrosis 
may not.   In this situation, corticosteroids 
often are used in conjunction with drug 
discontinuation. Discontinuation is more 
complex in patients on multiple drugs. In 
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this case, sequential discontinuation 
sometimes is performed beginning with the 
drug most likely to have caused the 
syndrome, then withdrawing the others until 
improvement occurs.16 
In our case, the presence of eosinophils 
in the lung tissue as well as the significant 
eosinophilia (25%) in the bronchoalveolar 
lavage confirmed the diagnosis of 
pulmonary eosinophilia with infiltrates. 
Prednisone was initiated because of the 
severity of symptoms and the presence of 
fibrosis on the pathology.  This case showed 
the possible deleterious effect of a 
commonly used medication. It also 
emphasized the importance of monitoring 
patients taking nitrofurantoin for prolonged 
periods, at least by history, and possibly 
regular chest x-rays and pulmonary function 
tests.17 
 
References 
1
 Medsafe. Prescriber update articles. 
Pulmonary reactions with nitrofurantoin.  
May 2002. Accessed at: http://www. 
medsafe.govt.nz/profs/PUarticles/nitrofura
nt.htm. 
2
 The Uppsala Monitoring Centre.  
Causality assessment of suspected adverse 
reactions.  Accessed at: http://www.who-
umc.org/DynPage.aspx?id=22682. 
3
 Fisk AA. Brief recording:  Anaphylactoid 
reaction to nitrofurantoin.  N Engl J Med 
1957; 256:1054. 
4
 Fawcett IW, Ibrahim NB. BOOP 
associated with nitrofurantoin. Thorax 
2001; 56:161. 
5
 Drug-induced lung disease: The price of 
progress.  Medical Staff Conference, 
University of California, San Francisco. 
Calif Med 1973; 119:48-55. 
6
 Meyer MM, Meyer RJ.  Nitrofurantoin-
induced pulmonary hemorrhage in a renal 
transplant recipient receiving immuno-
suppressive therapy: Case report and 
review of the literature.  J Urol 1994; 152: 
938-940.  
7
 Magee F, Wright JL, Chan N, et al.  Two 
unusual pathological reactions to 
nitrofurantoin: Case reports. Histo-
pathology 1986; 10:701-706. 
8
 Qureshi MM. Interstitial lung disease 
caused by chronic nitrofurantoin reaction; 
case report. Wis Med J 1984; 83:20-22. 
9
 Holmberg L, Boman G, Böttiger LE, 
Eriksson   B,   Spross    R,    Wessling    A. 
 
 
Adverse reactions to nitrofurantoin. 
Analysis of 921 reports. Am J Med 1980; 
69:733-738. 
10
 Holmberg L, Boman G.  Pulmonary 
reactions in nitrofurantoin. 447 cases 
reported to the Swedish Adverse Drug 
Reaction Committee 1966-1976. Eur J 
Respir Dis 1981; 62:180-189. 
11
 Sovijärvi AR, Lemola, M, Stenius, B, 
Idänpään-Heikkilä J.  Nitrofurantoin-
induced acute, subacute and chronic 
pulmonary reactions. Scand J Respir Dis 
1977; 58:41-50. 
12
 Suntres ZE, Shek PN.  Nitrofurantoin-
induced pulmonary toxicity.  In vivo 
evidence for oxidative stress-mediated 
mechanisms.  Biochem Pharmacol 1992; 
43:1127-1135. 
13
 Vaughan Jones R, Goldman L. Persistent 
eosinophilia after nitrofurantoin.  Lancet 
1968; 291:306. 
14
 Benzaquen-Forner H, Dournovo P, 
Tandjaoui-Lambiotte H, et al. [Hypoxic 
eosinophilic pneumonia in two patients 
treated with ACE inhibitors.]  (French.) 
Rev Mal Respir 1998; 15:804-810. 
15
 Citro LA, Gordon ME, Miller WT. 
Eosinophilic lung disease (or how to slice 
P.I.E.).  Am J Roentgenol Radium Ther 
Nucl Med 1973; 117:787-797. 
16
 Saukkonen JJ.  Pulmonary Eosinophilia.  
November 20, 2009.  Accessed at: 
http://emedicine.medscape.com/article/30
1070-overview. 
Kansas Journal of Medicine 2011               Nitrofurantoin-Induced Lung Toxicity 
10 
 
17
 Schwarz MI, King TE.  Interstitial Lung 
Disease. 4th edition.  Hamilton, ON:  BC 
Decker, 2003. 
18
 Parker G. Failure to adequately monitor 
liver and lung function. MDU J 2007; 23: 
24-25. 
Keywords:  nitrofurantoin, interstitial lung 
disease, drug toxicity, case report 
